A recent phase III trial showed a combination regimen with immunotherapy agents plus chemotherapy significantly reduced the risk of disease progression or death in patients with advanced non-squamous non-small cell lung cancer.
A recent study compared the effectiveness of stereotactic ablative body radiotherapy (SABR) with conventional full fractionated radiotherapy (CRT) in prolonging time to local failure in patients with inoperable stage I non-small cell lung cancer (NSCLC), presented at the International Association for the Study of Lung Cancer 18th Annual World Conference (October 15-
Despite the majority of radiation oncologists administering the National Comprehensive Cancer Network (NCCN) guideline-recommended thoracic radiotherapy schedule to patients with small-cell lung cancer, great variability still exists in dosing and fractionation, according to a recent survey.
A liquid biopsy that measures circulating lung tumor DNA at the end of treatment identifies patients with early non-small cell lung cancer (NSCLC) with a poor prognosis, according to research presented at the American Society for Radiation Oncology (ASTRO) annual meeting (September 24-27, 2017; San Diego, CA).
Patients with advanced non-small cell lung cancer (NSCLC) who undergo salvage chemotherapy are 30% more likely to achieve partial response if they have been treated with a PD-1/PD-L1 checkpoint inhibitor, according to a presentation at the European Lung Cancer Conference (Geneva, Switzerland; abstract 91PD).
Patients with lung cancer who are treated with immunotherapy may be at increased risk of severe adverse events after receiving the seasonal influenza vaccination, according to results of a study presented at the European Lung Cancer Conference (April 25, 2017; abstract 112P_PR).
None of the patients in a study with lung cancer and hepatic metastases experienced an objective response in their liver tumors after anti-PD1 therapy, according to research presented at ASCO’s Society for Immunotherapy of Cancer’s 2017 Clinical Immuno-Oncology Symposium (February 23-25, 2017; abstract 38).